The role of Mesothelin in tumor progression and targeted therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 276-280

  Tang, Zhewei ^a,b   Qian, Min ^a   Ho, Mitchell ^b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity ADCC; Apoptosis; Cell surface proteins; Cell survival proliferation; Complement dependent cytotoxicity CDC; Human monoclonal antibodies; Immunotoxin; Mesothelin; MORAb 009 amatuximab; MUC16 CA125; NF B; PI3K

Indexed keywords

AMATUXIMAB; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOTOXIN; INTERLEUKIN 6; MESOTHELIN; MUCIN; PACLITAXEL; PLATINUM; PROTEIN BCL 2; PROTEIN BCL XL; SS1P; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; BILE DUCT CARCINOMA; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE CONTROL; HUMAN; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; GPI-LINKED PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84874820023     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020014     Document Type: Review

References (40)

1. Chang, K.; Pastan, I.; Willingham, M.C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer, 1992, 50, 373-381.
2. Chang, K.; Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA, 1996, 93, 136-140.
3. Argani, P.; Iacobuzio-Donahue, C.; Ryu, B.; Rosty, C.; Goggins, M.; Wilentz, R.E.; Murugesan, S.R.; Leach, S.D.; Jaffee, E.; Yeo, C.J.; Cameron, J.L.; Kern, S.E.; Hruban, R.H. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res., 2001, 7, 3862-3868.
4. Ordonez, N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod. Pathol., 2003, 16, 192-197.
5. Hassan, R.; Kreitman, R.J.; Pastan, I.; Willingham, M.C. Localization of mesothelin in epithelial ovarian cancer. Appl. Immunohistochem. Mol. Morphol., 2005, 13, 243-247.
6. Hassan, R.; Bera, T.; Pastan, I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res., 2004, 10, 3937-3942.
7. Hassan, R.; Ho, M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer, 2008, 44, 46-53.
8. Ho, M.; Bera, T.K.; Willingham, M.C.; Onda, M.; Hassan, R.; FitzGerald, D.; Pastan, I. Mesothelin expression in human lung cancer. Clin. Cancer Res., 2007, 13, 1571-1575.
9. Dainty, L.A.; Risinger, J.I.; Morrison, C.; Chandramouli, G.V.; Bidus, M.A.; Zahn, C.; Rose, G.S.; Fowler, J.; Berchuck, A.; Maxwell, G.L. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol. Oncol., 2007, 105, 563-570.
10. Steinbach, D.; Onda, M.; Voigt, A.; Dawczynski, K.; Wittig, S.; Hassan, R.; Gruhn, B.; Pastan, I. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur. J. Haematol., 2007, 79, 281-286.
11. Ordonez, N.G. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol., 2003, 27, 1418-1428.
12. Yu, L.; Feng, M.; Kim, H.; Phung, Y.; Kleiner, D.E.; Gores, G.J.; Qian, M.; Wang, X.W.; Ho, M. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J. Cancer, 2010, 1, 141-149.
13. Bera, T.K.; Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Mol. Cell Biol., 2000, 20, 2902-1906.
14. Rump, A.; Morikawa, Y.; Tanaka, M.; Minami, S.; Umesaki, N.; Takeuchi, M.; Miyajima, A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem., 2004, 279, 9190-9198.
15. Li, M.; Bharadwaj, U.; Zhang, R.; Zhang, S.; Mu, H.; Fisher, W.E.; Brunicardi, F.C.; Chen, C.; Yao, Q. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol. Cancer Ther., 2008, 7, 286-296.
16. Bharadwaj, U.; Li, M.; Chen, C.; Yao, Q. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol. Cancer Res., 2008, 6, 1755-1765.
17. Bharadwaj, U.; Marin-Muller, C.; Li, M.; Chen, C.; Yao, Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis, 2011, 32, 1013-1024.
18. Bharadwaj, U.; Marin-Muller, C.; Li, M.; Chen, C.; Yao, Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol. Cancer, 2011, 10, 106.
19. Chang, M.C.; Chen, C.A.; Hsieh, C.Y.; Lee, C.N.; Su, Y.N.; Hu, Y.H.; Cheng, W.F. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem. J., 2009, 424, 449-458.
20. Cheng, W.F.; Huang, C.Y.; Chang, M.C.; Hu, Y.H.; Chiang, Y.C.; Chen, Y.L.; Hsieh, C.Y.; Chen, C.A. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br. J. Cancer, 2009, 100, 1144-1153.
21. Uehara, N.; Matsuoka, Y.; Tsubura, A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol. Cancer Res., 2008, 6, 186-193.
22. Yamaguchi, N.; Hattori, K.; Oh-eda, M.; Kojima, T.; Imai, N.; Ochi, N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J. Biol. Chem., 1994, 269, 805-808.
23. Sathyanarayana, B.K.; Hahn, Y.; Patankar, M.S.; Pastan, I.; Lee, B. Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. BMC. Struct. Biol., 2009, 9, 1.
24. Gubbels, J.A.; Belisle, J.; Onda, M.; Rancourt, C.; Migneault, M.; Ho, M.; Bera, T.K.; Connor, J.; Sathyanarayana, B.K.; Lee, B.; Pastan, I.; Patankar, M.S. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer, 2006, 5, 50.
25. Kaneko, O.; Gong, L.; Zhang, J.; Hansen, J.K.; Hassan, R.; Lee, B.; Ho, M. A binding domain on mesothelin for CA125/MUC16. J. Biol. Chem., 2009, 284, 3739-3749.
26. Xiang, X.; Feng, M.; Felder, M.; Connor, J.P.; Man, Y.G.; Patankar, M.S.; Ho, M. HN125: A novel immunoadhesin targeting MUC16 with potential for cancer therapy. J. Cancer, 2011, 2, 280-291.
27. Ho, M.; Hassan, R.; Zhang J.; Wang, Q.C.; Onda, M.; Bera, T.; Pastan, I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res., 2005, 11, 3814-3820.
28. Aggarwal, B.B.; Shishodia, S.; Sandur, S.K.; Pandey, M.K.; Sethi, G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol., 2006, 72, 1605-1621.
29. Aggarwal, B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell., 2004, 6, 203-208.
30. Prieve, M.G.; Moon, R.T. Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC. Dev. Biol., 2003, 3, 2.
31. Hucl, T.; Brody, J.R.; Gallmeier, E.; Iacobuzio-Donahue, C.A.; Farrance, I.K.; Kern, S.E. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res., 2007, 67, 9055-9065.
32. Ren, Y.R.; Patel, K.; Paun, B.C.; Kern, S.E. Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. J. Biol. Chem., 2011, 286, 11960-11969.
33. Chowdhury, P.S.; Viner, J.L.; Beers, R.; Pastan, I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA, 1998, 95, 669-674.
34. Chowdhury, P.S.; Pastan, I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol., 1999, 17, 568-572.
35. Hassan, R.; Bullock, S.; Premkumar, A.; Kreitman, R.J.; Kindler, H.; Willingham, M.C.; Pastan, I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res., 2007, 13, 5144-5149.
36. Kreitman, R.J.; Hassan, R.; Fitzgerald, D.J.; Pastan, I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer Res., 2009, 15, 5274-5279.
37. Hassan, R.; Ebel, W.; Routhier, E.L.; Patel, R.; Kline, J.B.; Zhang, J.; Chao, Q.; Jacob, S.; Turchin, H.; Gibbs, L.; Phillips, M.D.; Mudali, S.; Iacobuzio-Donahue, C.; Jaffee, E.M.; Moreno, M.; Pastan, I.; Sass, P.M.; Nicolaides, N.C.; Grasso, L. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun., 2007, 7, 20.
38. Hassan, R.; Cohen, S.J.; Phillips, M.; Pastan, I.; Sharon, E.; Kelly, R.J.; Schweizer, C.; Weil, S.; Laheru, D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin. Cancer Res., 2010,16, 6132-6138.
39. Feng, Y.; Xiao, X.; Zhu, Z.; Streaker, E.; Ho, M.; Pastan, I.; Dimitrov, D.S. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol. Cancer Ther., 2009, 8, 1113-1118.
40. Ho, M.; Feng, M.; Fisher, R.J.; Rader, C.; Pastan, I. A novel high-affinity human monoclonal antibody to mesothelin. Int. J. Cancer, 2011,128, 2020-2030.